The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa–Endemic Areas
Open accessAbstract
BACKGROUND: Implementation of an ivermectin-based community treatment strategy for the elimination of onchocerciasis or lymphatic filariasis has been delayed in Central Africa because of the occurrence of serious adverse events, including death, in persons with high levels of circulating Loa loa microfilariae. The LoaScope, a field-friendly diagnostic tool to quantify L. loa microfilariae in peripheral blood, enables rapid, point-of-care identification of persons at risk for serious adverse events. METHODS: A test-and-not-treat strategy was used in the approach to ivermectin treatment in the Okola health district in Cameroon, where the distribution of ivermectin was halted in 1999 after the occurrence of fatal events related to L. loa infection. The LoaScope was used to identify persons with an L. loa microfilarial density greater than 20,000 microfilariae per milliliter of blood, who were considered to be at risk for serious adverse events, and exclude them from ivermectin distribution. Active surveillance for posttreatment adverse events was performed daily for 6 days. RESULTS: From August through October 2015, a total of 16,259 of 22,842 persons 5 years of age or older (71.2% of the target population) were tested for L. loa microfilaremia. Among the participants who underwent testing, a total of 15,522 (95.5%) received ivermectin, 340 (2.1%) were excluded from ivermectin distribution because of an L. loa microfilarial density above the risk threshold, and 397 (2.4%) were excluded because of pregnancy or illness. No serious adverse events were observed. Nonserious adverse events were recorded in 934 participants, most of whom (67.5%) had no detectable L. loa microfilariae. CONCLUSIONS: The LoaScope-based test-and-not-treat strategy enabled the reimplementation of community-wide ivermectin distribution in a heretofore "off limits" health district in Cameroon and is a potentially practical approach to larger-scale ivermectin treatment for lymphatic filariasis and onchocerciasis in areas where L. loa infection is endemic. (Funded by the Bill and Melinda Gates Foundation and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gardon, J., Gardon-Wendel, N., Demanga-Ngangue, Kamgno, J., Chippaux, J.-P., & Boussinesq, M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11094-1 · Cited by 745
Self-citationWolbachia.Bacterial Endosymbionts of Filarial Nematodes
Taylor, M. J., Bandi, C., & Hoerauf, A. (2005) · Advances in Parasitology · doi:10.1016/s0065-308x(05)60004-8 · Cited by 425
Attributable and Unattributable Risks and Fractions and other Scenario Comparisons
Newson, R. B. (2013) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x1301300402 · Cited by 329
Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope
D’Ambrosio, M. V., Bakalar, M., Bennuru, S., Reber, C., Skandarajah, A., Nilsson, L., Switz, N., Kamgno, J., Pion, S., Boussinesq, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3480 · Cited by 237
Self-citationBoussinesq, M., Gardon, J., Gardon-Wendel, N., & Chippaux, J. (2003) · Filaria Journal · doi:10.1186/1475-2883-2-s1-s4 · Cited by 199
Self-citationThree probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis.
Boussinesq, M., Gardon, J., Gardon-Wendel, N., Kamgno, J., Ngoumou, P., & Chippaux, J. (1998) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1998.58.461 · Cited by 158
Self-citationA Rapid‐Format Antibody Card Test for Diagnosis of Onchocerciasis
Weil, G. J., Steel, C., Liftis, F., Li, B., Mearns, G., Lobos, E., & Nutman, T. B. (2000) · The Journal of Infectious Diseases · doi:10.1086/317629 · Cited by 141
Self-citationSevere adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areas
Chippaux, J., Boussinesq, M., Gardon, J., Gardon-Wendel, N., & Ernould, J.-C. (1996) · Parasitology Today · doi:10.1016/0169-4758(96)40006-0 · Cited by 128
Self-citationObligatory symbiotic Wolbachia endobacteria are absent from Loa loa
Büttner, D. W., Wanji, S., Bazzocchi, C., Bain, O., & Fischer, P. (2003) · Filaria Journal · doi:10.1186/1475-2883-2-10 · Cited by 110
Self-citationOcular findings after ivermectin treatment of patients with high Loa loa microfilaremia
Fobi, G., Gardon, J., Santiago, M. F. O., Ngangue, D., Gardon-Wendel, N., & Boussinesq, M. (2000) · Ophthalmic Epidemiology · doi:10.1076/0928-6586(200003)711-2ft027 · Cited by 42
Self-citation
Cited by
Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy
Fozouni, P., Son, S., Díaz de León Derby, M., Knott, G. J., Gray, C. N., D’Ambrosio, M. V., Zhao, C., Switz, N. A., Kumar, G. R., Stephens, S. I., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.001 · Cited by 1,047
Self-citationMechanical Strain and Bone Cell Function: A Review
Ehrlich, P. J., & Lanyon, L. E. (2002) · Osteoporosis International · doi:10.1007/s001980200095 · Cited by 512
The public health control of scabies: priorities for research and action.
Engelman, D., Cantey, P. T., Marks, M., Solomon, A. W., Chang, A. Y., Chosidow, O., Enbiale, W., Engels, D., Hay, R. J., Hendrickx, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31136-5 · Cited by 223
Self-citationMoxidectin: an oral treatment for human onchocerciasis
Milton, P., Hamley, J. I. D., Walker, M., & Basáñez, M.-G. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1792772 · Cited by 211
Efficacy of High-Dose Albendazole with Ivermectin for Treating Imported Loiasis, Italy
Gobbi, F., Buonfrate, D., Tamarozzi, F., Degani, M., Angheben, A., & Bisoffi, Z. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2508.190011 · Cited by 21
Metadata
- Authors
- Kamgno, J., Pion, S. D., Chesnais, C. B., Bakalar, M. H., D’Ambrosio, M. V., Mackenzie, C. D., Nana-Djeunga, H. C., Gounoue-Kamkumo, R., Njitchouang, G.-R., Nwane, P., Tchatchueng-Mbouga, J. B., Wanji, S., Stolk, W. A., Fletcher, D. A., Klion, A. D., Nutman, T. B., & Boussinesq, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-23
- Volume
- 377
- Issue
- 21
- Pages
- 2044-2052
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2767594581
- Cited by
- 297
- References
- 12
- FWCI
- 17.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.